Резистентные стафилококки: проблемы антибиотикотерапии

 1. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997; 10 (3): 505-20.
2. Eriksen NH, Espersen F, Rosdahl VT, Jensen K. Carriage of Staphylococcus aureus among 104 healthy persons during a 19-month period. Epidemiol Infect 1995; 115 (1): 51 60.
3. Nouwen JL, Ott A, Kluytmans-Vandenbergh MF et al. Predicting the Staphylococcus aureus nasal carrier state: derivation and validation of a "culture rule". Clin Infect Dis 2004; 39 (6): 806-11.
4. Hu L, Umeda A, Kondo S, Amako K. Typing of Staphylococcus aureus colonising human nasal carriers by pulsed-field gel electrophoresis. J Med Microbiol 1995; 42 (2): 127-32.
5. Jevons M: 'Celbenin'-resistant staphylococci. BMJ 1961; 1: 124.
6. Ito T, Katayama Y, Hiramatsu K. Cloning and nucleotide sequence determination of the entire mec DNA of pre-methicillin-resistant Staphylococcus aureus N315. Antimicrob Agents Chemother 1999; 43 (6): 1449-58.
7. Hiramatsu K, Cui L, Kuroda M, Ito T. The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol 2001; 9 (10): 486-93.
8. Wu S, Piscitelli C, de Lencastre H, Tomasz A. Tracking the evolutionary origin of the methicillin resistance gene: cloning and sequencing of a homologue of mecA from a methicillin susceptible strain of Staphylococcus sciuri. Microb Drug Resist 1996; 2 (4): 435-41.
9. Archer GL, Thanassi JA, Niemeyer DM, Pucci MJ. Characterization of IS1272, an insertion sequence-like element from Staphylococcus haemolyticus. Antimicrob Agents Chemother 1996; 40 (4): 924-9.
10. Cosgrove SE, Sakoulas G, Perencevich EN et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003; 36 (1): 53-9.
11. Page MG. Anti-MRSA beta-lactams in development. Curr Opin Pharmacol 2006; 6 (5): 480-5.
12. Rossolini GM. Redesigning beta-lactams to combat resistance: summary and conclusions. Clin Microbiol Infect 2007; 13 (Suppl. 2): 30-3.
13. Bush K, Heep M, Macielag MJ, Noel GJ. Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy. Expert Opin Investig Drugs 2007; 16 (4): 419-29.
14. Jones ME. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 2007; 13 (Suppl. 2): 17-24.
15. Pate K, Nolan R, Bannerman T, Feldman S. Methicillin-resistant Staphylococcus aureus in the community. Lancet 1995; 346: 978.
16. Gorak E, Yamada S, Brown J. Community-acquired methicillinresistant Staphylococcus aureus in hospitalized adults and children without known risk factors. Clin Infect Dis 1999; 29: 797-800.
17. Baranovich T, Yamamoto T, Potapov V. The first isolation of Panton-Valentine leukocidin (PVL) positive community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) in Russia. Euro Surveill 2007; 12 (3): E070315.4. http://www.eurosurveillance.org/ew/2007/070315.asp#4
18. Small P, Chambers H. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990; 34: 1227-31.
19. Levine D, Fromm B, Reddy B. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115: 674-80.
20. Chambers H, Miller R, Newman M. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. Ann Intern Med 1988; 109: 619-24.
21. Siebert W, Moreland N, Williams T. Synergy of vancomycin plus cefazolin or cephalothin against methicillin-resistance Staphylococcus epidermidis. J Infect Dis 1979; 139: 452-7.
22. Hiramatsu K et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350: 1668-71.
23. Hiramatsu K et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-6.
24. Noble W, Virani Z, Cree R. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol. Lett 1992; 93: 195-8.
25. Livermore DM. Epidemiology of antibiotic resistance. Intensive Care Medicine 2000; 26: S14-21.
26. Public Health Laboratory Service. Staphylococcus aureus bacteraemia: England and Wales January to December 2000. Communicable Disease Report Weekly 2001; 11: 3-5.
27. Arakawa Y, Ike Y, Nagasawa M et al. Trends in antimicrobial-drug resistance in Japan. Emerg Infect Dis 2000; 6: 572-5.
28. Centers for Disease Control and Prevention. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003; 31: 481-98.
29. Сидоренко С.В., Резван С.П., Грудинина С.А., Кротова Л.А., Стерхова Г.В. Результаты многоцентрового исследования чувствительности стафилококков к антибиотикам в Москве и Санкт-Петербурге. Антибиот. и химиотер. 1998; 43 (7): 15-25.
30. Дехнич А.В., Эйдельштейн И.А., Нарезкина А.Д., и др. Эпидемиология резистентности нозокомиальных штаммов Staphylococcus aureus в России: результаты многоцентрового исследования. Клинич. микробиол. и антимикроб. химиотер. 2002; 4 (4): 325-36.
31. Jensen A, Wachmann C, Espersen F et al. Treatment and outcome of Staphylococcus aureus bacteremia. Arch Intern Med 2002; 162: 25-32.
32. Shinabarger DL, Marotti KR, Murray RW et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother 1997; 41: 2132-6.
33. Shinabarger D. Mechanism of action of the oxazolidinone antibacterial agents. Expert Opin Invest Drugs 1999; 8: 1195-202.
34. Tsiodras S, Gold HS, Sakoulas G et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358: 207-8.
35. Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or b-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 2008; 8: 53-66.
36. Climo M, Patron R, Archer G. Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin. Antimicrob. Agents Chemother 1999; 43: 1747-53.
37. Srinivasan A, Dick J, Perl T. Vancomycin resistance in Staphylococci. Clin Microbiol Rev 2002; 15: 430-8.
38. CDC. Staphylococcus aureus resistant to vancomycin. United States, 2002. MMWR, 2002; 51: 565-7.
39. CDC. Staphylococcus aureus resistant to vancomycin. United States, 2002. MMWR, 2002; 51: 902-3.